AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|February 25, 2007
Oriana Schwindt
Advertisement
Oriana Schwindt
Associate Editor
Oriana Schwindt worked as a reporter, writer, and researcher at several national publications (among them, BusinessWeek and Entertainment Weekly) before joining the Pharm Exec team as Associate Editor. She holds a BS in Journalism from the Medill School of Journalism at Northwestern University.
Advertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Advertisement
Advertisement
Trending on PharmExec
1
Understanding the Latest with MFN Pricing and What It Means to Pharma
2
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
3
The Battle to Own the GLP-1 Patient Journey
4
Novo Announces Drug Discovery Collaboration with Anthropic
5